Up to 85% of patients treated with 400 mg imatinib achieve a complete cytogenetic response (CCR) and 40–60% achieve a major molecular response (MMR). These responses are stable in many patients ...

The TOPS study randomized patients 2:1 to receive either 800 mg/day or 400 mg/day imatinib. However, at 12 months the authors could not detect a statistically significant difference in MMR (46 vs ...